Evidence map›Paper›PMID 39824674›Full record

ArticleTrends in pharmacological sciences2025

IRAK4: potential therapeutic target for airway disease exacerbations.

Joseph A Jude, Reynold A Panettieri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in pharmacological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joseph A JudeRutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, 89 French Street, Suite 4210, New Brunswick, NJ 08901, USA.
Reynold A PanettieriRutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, 89 French Street, Suite 4210, New Brunswick, NJ 08901, USA. Electronic address: rp856@rbhs.rutgers.edu.

Funding

Project 4 - OGR1- and TSPO- dependent mechanisms mediated by benzodiazepines affecting ASM contractionP01HL114471 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI LIGGETT, STEPHEN B · 2013 to 2023
$23.9M
NHLBI NIH HHS P01 HL114471
6 · The paper itself

Abstract

Inflammatory lung diseases represent a significant healthcare burden. There is an unmet need for identifying therapeutic targets for inflammatory lung diseases, such as asthma, and chronic obstructive pulmonary disease (COPD). In a recent study, Sayers et al. validate the inhibition of interleukin (IL)-1 receptor-associated kinase (IRAK)-4 as a potential therapeutic strategy toward lung inflammation and inflammatory airway diseases more generally.

Indexed as

AsthmaInterleukin-1 Receptor-Associated KinasesProtein Kinase InhibitorsPulmonary Disease, Chronic ObstructiveAnimalsHumansMolecular Targeted TherapyInterleukin-1 Receptor-Associated KinasesIRAK4 protein, humanProtein Kinase InhibitorsCOPDinterleukin-1 receptor-associated kinase 4lung inflammationToll-like receptor, asthma

Identifiers

PMID39824674
PMCPMC12801350

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.